On Wednesday, Mankind Pharma said that it has agreed with Dr Reddy’s Laboratories (DRL) to acquire two of its brands – one asthma and one infant care brand. The deal size was not disclosed.

• UDAN Scheme Improving Regional Connectivity 
• India’s GDP Might Slip to 6.5%; ICRA Maintains it at 7% for FY25
• Consumer Inflation in UK Grew in October 
• Rajesh Power Services Ltd IPO: GMP, Lot Size, Price Band & Key Dates
• Addverb Technologies Planning to Launch Advanced Humanoid Robots in 2025

Combihale, a drug used for treating asthma and chronic obstructive pulmonary disease, has a category market size of Rs 900 crore, growing at 14 per cent (IQVIA). Daffy, a soap-free moisturizing bar for infants, operates in a market category valued at Rs 1000 crore and is growing at 18 per cent (IQVIA).

The company said that the acquisition of Combihale is expected to strengthen Mankind’s presence in the inhalation respiratory market segment.